Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Strober

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|January 5, 2024
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)Bruce Strober, Hervé Bachelez, Jeffrey Crowley, et al.
The British Journal of Dermatology|March 27, 2023
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trialBruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 22, 2025
Mission impossible? Caveats in interpreting and comparing long-term efficacy in biologic studies for moderate-to-severe plaque psoriasisRichard G Langley, Alexander Egeberg, Melinda Gooderham, et al.
The British Journal of Dermatology|January 23, 2023
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trialDiamant Thaçi, Ron Vender, Menno A de Rie, et al.
Dermatology and Therapy|August 6, 2025
Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective StudyApril Armstrong, Bruce Strober, Paolo Gisondi, et al.
Dermatology and Therapy|March 21, 2025
Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis TrialsApril W Armstrong, Leon Kircik, Linda Stein Gold, et al.
The British Journal of Dermatology|January 25, 2025
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension periodRichard B Warren, Mark Lebwohl, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.
Dermatology and Therapy|July 2, 2026
Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque PsoriasisJeffrey Crowley, Eingun James Song, Linda Stein-Gold, et al.
American Journal of Clinical Dermatology|August 31, 2025
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb StudiesJoseph F Merola, Richard B Warren, Diamant Thaçi, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
Journal of the European Academy of Dermatology and Venereology : JEADV|January 5, 2024
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)Bruce Strober, Hervé Bachelez, Jeffrey Crowley, et al.
The British Journal of Dermatology|March 27, 2023
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trialBruce Strober, Yayoi Tada, Ulrich Mrowietz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 22, 2025
Mission impossible? Caveats in interpreting and comparing long-term efficacy in biologic studies for moderate-to-severe plaque psoriasisRichard G Langley, Alexander Egeberg, Melinda Gooderham, et al.
The British Journal of Dermatology|January 23, 2023
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trialDiamant Thaçi, Ron Vender, Menno A de Rie, et al.
Dermatology and Therapy|August 6, 2025
Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective StudyApril Armstrong, Bruce Strober, Paolo Gisondi, et al.
Dermatology and Therapy|March 21, 2025
Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis TrialsApril W Armstrong, Leon Kircik, Linda Stein Gold, et al.
The British Journal of Dermatology|January 25, 2025
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension periodRichard B Warren, Mark Lebwohl, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.
Dermatology and Therapy|July 2, 2026
Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque PsoriasisJeffrey Crowley, Eingun James Song, Linda Stein-Gold, et al.
American Journal of Clinical Dermatology|August 31, 2025
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb StudiesJoseph F Merola, Richard B Warren, Diamant Thaçi, et al.
Pageof 13